New Mouse Model Accelerates Testing for Parkinson's Neuroprotective Therapies

The progressive loss of dopaminergic neurons in the substantia nigra is a hallmark of Parkinson's disease (PD), leading to severe motor and cognitive impairments. Despite extensive research, effective neuroprotective therapies that halt or reverse this neurodegeneration remain elusive. This challenge is partly due to limitations in existing preclinical models that accurately mimic the complex, progressive nature of human PD, hindering the efficient screening of potential drug candidates.

The MPTP-induced model successfully replicated significant nigrostriatal dopaminergic degeneration, showing a 60% reduction in TH+ neurons in the substantia nigra and a 70% decrease in striatal dopamine levels in untreated controls compared to healthy mice. Treatment with NeuroPep-1 significantly mitigated this damage. NeuroPep-1 treatment resulted in a remarkable 45% preservation of dopaminergic neurons in the substantia nigra compared to the untreated MPTP group (p<0.001). Furthermore, striatal dopamine levels in the NeuroPep-1 treated group were 30% higher than in controls (p<0.01), indicating a substantial neuroprotective effect. Behavioral tests also showed a 2.5-fold improvement in motor coordination and balance in treated mice compared to untreated controls (p<0.005), demonstrating functional recovery.